InvestmentPitch Media Video Discusses Blackhawk Growth's Acquisition of MindBio Therapeutics, a Clinical Stage Drug Development Company Pioneering Psychedelic Micro-Dosing Research - Video Available on Investmentpitch.com

Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) -  Blackhawk Growth Corp. (CSE: BLR) (FSE: 0JJ0) (OTCBB: BLRZF), an investment holding company, is acquiring MindBio Therapeutics. MindBio Therapeutics (www.MindBioTherapeutics.com), an arms-length, privately held clinical stage drug development company, is pioneering psychedelic micro-dosing research and is advancing emerging therapies to treat a range of debilitating health conditions such as depression, anxiety, chronic pain, cognitive impairment and PTSD.

InvestmentPitch.com has produced a "video" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Blackhawk" in the search box.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=ffSCwrZ1R_A

In the world's first clinical trial of its kind, the company has started Phase 1 clinical trials at the University of Auckland in New Zealand, in a safety study of 80 participants micro-dosing LSD to patients, which will take the drug at home as they would any other medication. The study has received regulatory approval and government funding for the importing of LSD, laboratory work using the drug, and approvals for participants to be prescribed the drug.

Approvals have also been received for Phase 2 clinical trials involving micro-dosing LSD in late-stage cancer patients experiencing end of life distress. MindBio Therapeutics is also pioneering the development of micro-dose formulations and a range of technology and artificial intelligence applications to ensure the safe dosage, use and administration of psychedelic medicines in the community. Early indications show that LSD is tolerated well in micro-doses and has a lower side effect profile than currently prescribed anti-depressant drugs.

Justin Hanka, Co-Founder and Director of MindBio Therapeutics, stated: "We are excited to become part of the Blackhawk portfolio, which expands our investor reach to the capital markets in North America and we are now truly a global company with connections in Australia, New Zealand and Canada. We are excited by the prospect of accelerating our clinical research micro-dosing psychedelic medicines in Phase 2 clinical trials and the next steps towards commercialisation."

Frederick Pels, CEO of Blackhawk, added: "The acquisition of MindBio Therapeutics will help to scale our life science and psychedelic portfolio. Complementing our current assets, a clinical trial and a management team with decades of experience in the health sector will enable Blackhawk and MindBio Therapeutics to be leaders in the legal psychedelic treatment industry that we believe will only continue to grow exponentially. We look forward to updating our shareholders with our progress over the coming months."

To close the transaction, Blackhawk Growth is issuing approximately 22.1 million shares. MindBio Therapeutics recently completed an equity financing for proceeds of approximately AUD $1.3 million, which gave it sufficient working capital to complete its Phase 1 clinical trials.

Blackhawk, an investment holding company, has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. For more information on its portfolio of companies, please watch the "video".

The shares are trading at $0.50. For more information, please visit the company's website www.BlackhawkGrowth.com, contact Frederick Pels, CEO, at 403-991-7737 or by email fred@BlackhawkGrowth.com.

About InvestmentPitch Media

Investmentpitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/95697